Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
October 08, 2024 07:30 ET
|
Traws Pharma, Inc.
Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability...
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
September 20, 2024 07:30 ET
|
Traws Pharma, Inc.
Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws’ Further Transformation and Growth Director James J Marino Also to Step Down from Traws Board After a Decade of...
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
September 17, 2024 16:05 ET
|
Traws Pharma, Inc.
Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws’ shares expected to begin trading on...
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
August 15, 2024 07:00 ET
|
Traws Pharma, Inc.
Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical...
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
May 23, 2024 08:00 ET
|
Traws Pharma, Inc.
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate